242 related articles for article (PubMed ID: 24607340)
1. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes.
Sahini N; Borlak J
Prog Lipid Res; 2014 Apr; 54():86-112. PubMed ID: 24607340
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.
Sanyal AJ
Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):46-53. PubMed ID: 16265100
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of intrahepatic triglyceride accumulation.
Ress C; Kaser S
World J Gastroenterol; 2016 Jan; 22(4):1664-73. PubMed ID: 26819531
[TBL] [Abstract][Full Text] [Related]
4. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.
Mashek DG
Mol Metab; 2021 Aug; 50():101115. PubMed ID: 33186758
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of lipid droplet proteins in liver diseases.
Carr RM; Ahima RS
Exp Cell Res; 2016 Jan; 340(2):187-92. PubMed ID: 26515554
[TBL] [Abstract][Full Text] [Related]
6. Pathology of nonalcoholic fatty liver disease.
Yeh MM; Brunt EM
Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
[TBL] [Abstract][Full Text] [Related]
7. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
[TBL] [Abstract][Full Text] [Related]
8. Hepatic lipid droplet homeostasis and fatty liver disease.
Seebacher F; Zeigerer A; Kory N; Krahmer N
Semin Cell Dev Biol; 2020 Dec; 108():72-81. PubMed ID: 32444289
[TBL] [Abstract][Full Text] [Related]
9. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease.
Croci I; Byrne NM; Choquette S; Hills AP; Chachay VS; Clouston AD; O'Moore-Sullivan TM; Macdonald GA; Prins JB; Hickman IJ
Gut; 2013 Nov; 62(11):1625-33. PubMed ID: 23077135
[TBL] [Abstract][Full Text] [Related]
10. A theoretical study of lipid accumulation in the liver-implications for nonalcoholic fatty liver disease.
Schleicher J; Guthke R; Dahmen U; Dirsch O; Holzhuetter HG; Schuster S
Biochim Biophys Acta; 2014 Jan; 1841(1):62-9. PubMed ID: 23999488
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis.
Anderson N; Borlak J
Pharmacol Rev; 2008 Sep; 60(3):311-57. PubMed ID: 18922966
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
Schuppan D; Schattenberg JM
J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
[TBL] [Abstract][Full Text] [Related]
13. Hepatic lipid droplet biology: Getting to the root of fatty liver.
Mashek DG; Khan SA; Sathyanarayan A; Ploeger JM; Franklin MP
Hepatology; 2015 Sep; 62(3):964-7. PubMed ID: 25854913
[TBL] [Abstract][Full Text] [Related]
14. The lipid droplet as a potential therapeutic target in NAFLD.
Goh VJ; Silver DL
Semin Liver Dis; 2013 Nov; 33(4):312-20. PubMed ID: 24222089
[TBL] [Abstract][Full Text] [Related]
15. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD).
Musso G; Gambino R; Cassader M
Prog Lipid Res; 2009 Jan; 48(1):1-26. PubMed ID: 18824034
[TBL] [Abstract][Full Text] [Related]
16. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Cusi K
Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
[TBL] [Abstract][Full Text] [Related]
17. Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis.
Straub BK; Stoeffel P; Heid H; Zimbelmann R; Schirmacher P
Hepatology; 2008 Jun; 47(6):1936-46. PubMed ID: 18393390
[TBL] [Abstract][Full Text] [Related]
18. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.
Nakamuta M; Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Yada M; Yada R; Takemoto R; Fukuizumi K; Harada N; Taketomi A; Maehara Y; Nakashima M; Enjoji M
Int J Mol Med; 2008 Nov; 22(5):663-7. PubMed ID: 18949388
[TBL] [Abstract][Full Text] [Related]
19. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
[TBL] [Abstract][Full Text] [Related]
20. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
